EGIS-7625
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C18H22N4O2 |
Molar mass | 326.400 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
EGIS-7625 is a selective and competitive 5-HT2B receptor antagonist. It is experimentally proven to be directly associated with smooth stomach muscle constriction of white rats in vivo, and variably effective in provoking a similar response in in vitro human stomach cells. In high blood concentrations, it causes mild constriction of rabbit pulmonary arteries.[1]
References
- ↑ Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, et al. (2003). "Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist". Cardiovascular Drugs and Therapy. 17 (5–6): 427–34. doi:10.1023/B:CARD.0000015857.96371.43. PMID 15107597. S2CID 11532969.
Simple piperazines (no additional rings) |
|
---|---|
Phenylpiperazines |
|
Benzylpiperazines | |
Diphenylalkylpiperazines (benzhydrylalkylpiperazines) |
|
Pyrimidinylpiperazines |
|
Pyridinylpiperazines |
|
Benzo(iso)thiazolylpiperazines | |
Tricyclics (piperazine attached via side chain) |
|
Others/Uncategorized |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.